WORCESTER, Mass. | June 23, 2026
Leal Therapeutics has announced that the first patient has been dosed in the NeurALS Phase 1/2 clinical trial evaluating LTX-002, a first-in-class antisense oligonucleotide (ASO) designed to treat amyotrophic lateral sclerosis (ALS) by restoring lipid metabolism in the central nervous system (CNS). The investigational therapy targets SPTLC1, a key enzyme involved in sphingolipid production, representing a novel disease-modifying strategy that has the potential to benefit both sporadic and genetic forms of ALS. The milestone marks the first clinical evaluation of this innovative neuro-metabolic approach and represents an important step toward developing new treatment options for a devastating neurodegenerative disease with significant unmet medical need.
Novel Lipid Metabolism Strategy Targets ALS Disease Biology
LTX-002 is an intrathecally administered antisense oligonucleotide developed to reduce the activity of SPTLC1, a core component of the serine palmitoyltransferase (SPT) enzyme complex responsible for sphingolipid production. Excessive SPT activity can lead to the accumulation of ceramides and sphingolipids, molecules increasingly associated with motor neuron toxicity and disease progression in both inherited and sporadic forms of ALS. By lowering SPT activity, LTX-002 aims to restore healthy lipid balance within the central nervous system, potentially protecting motor neurons from degeneration. Preclinical studies have demonstrated that SPT inhibition may reduce neurodegeneration and improve outcomes in models of ALS and related neurological disorders, supporting further clinical development of this first-in-class therapeutic approach.
Phase 1/2 NeurALS Trial Evaluates Safety and Target Engagement
The NeurALS (LTX-002-101; NCT07660614) study is a first-in-human, randomized, blinded, and placebo-controlled Phase 1/2 clinical trial enrolling adults with both genetic and sporadic ALS. The primary objectives are to evaluate the safety, tolerability, and pharmacokinetics of LTX-002, while exploratory endpoints will assess evidence of target engagement and potential biological activity. Researchers will measure cerebrospinal fluid (CSF) SPTLC1 protein levels, sphingolipid concentrations, plasma neurofilament light chain (NfL) as a marker of neurodegeneration, and important clinical outcomes including the ALS Functional Rating Scale-Revised (ALSFRS-R), pulmonary vital capacity, and muscle strength. These biomarkers are expected to provide valuable insights into the therapy’s mechanism of action and its potential to slow disease progression.
Advertisement
First Clinical Test of a New Neuro-Metabolic ALS Therapy
According to Leal Therapeutics, increasing scientific evidence suggests that dysregulated lipid metabolism plays an important role in the progression of amyotrophic lateral sclerosis, making it a promising therapeutic target. Company leadership described the first patient dosing as a significant milestone for both the organization and the broader ALS community, marking the transition of LTX-002 from laboratory research into human clinical evaluation. By integrating human genetics, biomarker research, and brain-penetrant therapeutic design, Leal Therapeutics is advancing a new generation of neuro-metabolic medicines aimed at addressing diseases with limited treatment options. If successful, LTX-002 could establish a completely new therapeutic strategy for ALS, potentially offering meaningful benefits for patients affected by both inherited and sporadic forms of this progressive and fatal neurological disorder.
Source: Leal Therapeutics press release
